Express News | Tourmaline Bio Inc Files for Mixed Shelf of up to $350 Mln - SEC Filing

BreakingsNov 8 06:25

Talaris Therapeutics GAAP EPS of -$0.78 Beats by $0.05

Seeking AlphaNov 8 00:23

Tourmaline Bio | 10-Q: Quarterly report

SECNov 7 21:28 · Announcements

Tourmaline Bio Q3 2024 GAAP EPS $(0.78) Beats $(0.84) Estimate, Cash, Cash Equivalents And Investments Of $314.4M, Providing Cash Runway Into 2027

BenzingaNov 7 20:57

Tourmaline Bio 3Q Loss/Shr 78c >TRML

Dow JonesNov 7 20:36

Press Release: Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Dow JonesNov 7 20:30